JP5753185B2 - プロリン誘導体 - Google Patents

プロリン誘導体 Download PDF

Info

Publication number
JP5753185B2
JP5753185B2 JP2012542178A JP2012542178A JP5753185B2 JP 5753185 B2 JP5753185 B2 JP 5753185B2 JP 2012542178 A JP2012542178 A JP 2012542178A JP 2012542178 A JP2012542178 A JP 2012542178A JP 5753185 B2 JP5753185 B2 JP 5753185B2
Authority
JP
Japan
Prior art keywords
compound
mmol
prepared
same manner
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012542178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512915A5 (enExample
JP2013512915A (ja
Inventor
チャーン，ジゥ−ハゥアー
チャオ，ユ−シェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of JP2013512915A publication Critical patent/JP2013512915A/ja
Publication of JP2013512915A5 publication Critical patent/JP2013512915A5/ja
Application granted granted Critical
Publication of JP5753185B2 publication Critical patent/JP5753185B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
JP2012542178A 2009-12-04 2010-12-02 プロリン誘導体 Expired - Fee Related JP5753185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26658409P 2009-12-04 2009-12-04
US61/266,584 2009-12-04
PCT/US2010/058672 WO2011068941A2 (en) 2009-12-04 2010-12-02 Proline derivatives

Publications (3)

Publication Number Publication Date
JP2013512915A JP2013512915A (ja) 2013-04-18
JP2013512915A5 JP2013512915A5 (enExample) 2014-01-23
JP5753185B2 true JP5753185B2 (ja) 2015-07-22

Family

ID=44082623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542178A Expired - Fee Related JP5753185B2 (ja) 2009-12-04 2010-12-02 プロリン誘導体

Country Status (10)

Country Link
US (1) US8415482B2 (enExample)
EP (1) EP2507232B1 (enExample)
JP (1) JP5753185B2 (enExample)
KR (1) KR101768946B1 (enExample)
CN (1) CN102482269B (enExample)
AU (1) AU2010325980B2 (enExample)
CA (1) CA2781140C (enExample)
MY (1) MY179840A (enExample)
TW (1) TWI429645B (enExample)
WO (1) WO2011068941A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
US8541424B2 (en) * 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) * 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PL2368890T3 (pl) * 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20140127158A1 (en) * 2012-11-08 2014-05-08 National Health Research Institute Combination therapy for hepatitis c virus infection
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104774194B (zh) * 2014-01-09 2018-01-30 正大天晴药业集团股份有限公司 氘代的丙型肝炎病毒抑制剂
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法
CN120390748A (zh) * 2022-10-28 2025-07-29 国家健康医学研究所 磷脂酰肌醇3-激酶的新型抑制剂
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511573A (ja) * 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
NZ619205A (en) * 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
CN102482269B (zh) 2015-07-29
KR101768946B1 (ko) 2017-08-17
CA2781140C (en) 2017-10-24
WO2011068941A3 (en) 2011-11-17
JP2013512915A (ja) 2013-04-18
CA2781140A1 (en) 2011-06-09
US8415482B2 (en) 2013-04-09
KR20120102690A (ko) 2012-09-18
TWI429645B (en) 2014-03-11
WO2011068941A2 (en) 2011-06-09
EP2507232B1 (en) 2019-03-20
TW201120035A (en) 2011-06-16
CN102482269A (zh) 2012-05-30
AU2010325980A1 (en) 2012-06-14
EP2507232A2 (en) 2012-10-10
EP2507232A4 (en) 2013-12-18
AU2010325980B2 (en) 2016-04-07
MY179840A (en) 2020-11-18
US20110136799A1 (en) 2011-06-09
HK1171439A1 (zh) 2013-03-28

Similar Documents

Publication Publication Date Title
JP5753185B2 (ja) プロリン誘導体
DE60124718T2 (de) Inhibitoren für virale polymerase
ES2394441T3 (es) Inhibidores de IAP
CN102414199B (zh) 二芳基醚
EA035500B1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
MXPA05004435A (es) Derivados de 1-acil-pirrolidina para el tratamiento de infecciones virales.
WO2011153588A1 (en) Viral polymerase inhibitors
KR20010031912A (ko) 벤조티아졸 단백질 티로신 키나제 억제제
CN101273038A (zh) 丙型肝炎病毒的大环化合物抑制剂
EA020580B1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
EA014646B1 (ru) Макроциклические ингибиторы вируса гепатита с
CN101977621A (zh) 氟化三肽hcv丝氨酸蛋白酶抑制剂
KR20140027076A (ko) 치환된 아졸, 항바이러스 활성 성분, 약학적 조성물, 이의 제조방법 및 이의 용도
WO2006007693A1 (en) Viral polymerase inhibitors
WO2003037894A1 (en) 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2014534206A (ja) Ｃ型肝炎ウイルス阻害剤
WO2001055123A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
CA2585170A1 (en) 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
CN105658625A (zh) 作为细胞坏死阻碍剂的吲哚酰胺化合物
WO2009038411A2 (en) Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety
EP4282862A1 (en) Flavivirus inhibitors
EP1506197A1 (en) Acyl bicyclic derivatives of pyrrol
HK1171439B (en) Proline derivatives
JPH08501567A (ja) レニン阻害ｎ−（２−アミノ−２−オキソエチル）ブタンジアミド誘導体
EP4563146A1 (en) Flavivirus inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150521

R150 Certificate of patent or registration of utility model

Ref document number: 5753185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees